Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PTGES | O14684 | 1/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.57 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 1/20 | 0.55 |
| ▸ | RHOC | P08134 | 1/20 | 0.55 |
| ▸ | RHOA | P61586 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767063 | 0.94 | RHOC (0.63) | KCNK3LMNAMAPTRAB9ANPC1 | |
| SCHEMBL28230040 | 0.94 | NPC1 (0.66) | KCNK3LMNAMAPTRAB9ANPC1 | |
| SCHEMBL3764441 | 0.87 | RAB9A (0.78) | KCNK3MAPTRAB9ANPC1MEN1 | |
| SCHEMBL3779837 | 0.87 | PTGES (0.69) | KCNK3RAB9ANPC1PTGS1PTGES | |
| SCHEMBL3771069 | 0.82 | NPC1 (0.78) | KCNK3RAB9ANPC1MEN1KMT2A | |
| SCHEMBL3771629 | 0.82 | NPC1 (0.66) | KCNK3RAB9ANPC1MEN1KMT2A | |
| SCHEMBL3776712 | 0.82 | RAB9A (0.67) | KCNK3RAB9ANPC1MEN1HTT | |
| SCHEMBL3769427 | 0.82 | NPC1 (0.66) | RAB9ANPC1MEN1KMT2A | |
| SCHEMBL3770483 | 0.82 | KMT2A (0.62) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4433745 | 0.81 | NPC1 (0.73) | MAPTRAB9ANPC1PTGS1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | KCNK3 1692/4885LMNA 2648/4885MAPT 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.